Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentProteomic-Based Approaches for the Study of Cytokines in Lung CancerThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisNew targeted treatments for non-small-cell lung cancer - role of nivolumabPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?The steady progress of targeted therapies, promising advances for lung cancerCIViC databaseTrends and advances in tumor immunology and lung cancer immunotherapyRecent Advances in Immunotherapy in Metastatic NSCLCThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentThe transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcomeImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Real-world data on nivolumab treatment of non-small cell lung cancer.Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Current state of immunotherapy for non-small cell lung cancer.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancerInflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeOverexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisLocal Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.The Preoperative Neutrophil-To-Lymphocyte Ratio Is a Novel Immune Parameter for the Prognosis of Esophageal Basaloid Squamous Cell Carcinoma.Checkpoint Blockade in Lung Cancer and Mesothelioma.Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.Molecular Imaging of Immunotherapy Targets in Cancer.A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapySecond-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
P2860
Q26738359-B8262374-FF31-4C9C-9AA1-A1EF6820C91EQ26738539-55455774-F815-4B5F-BB5C-879E56AE23B8Q26740280-C493DAB3-112A-484A-8D8E-CA52B2A258C2Q26740988-E6526E13-996D-412E-A0B1-038B5415310FQ26741101-E10E501E-2ED6-4D64-B1B7-F26F8A37E384Q26746895-4C7DBE20-CBEA-4570-9702-8CAE591154D3Q27612411-611A5C63-0C10-4A89-911B-E60F7B70941DQ28067674-63A17CFF-77D4-41C4-B765-BA6939A6BFA9Q28069323-3523FE4C-ED86-4217-BE35-C8BF33FC248CQ28069924-197CB756-E5DD-45C0-A158-D5287F764628Q28076294-5743EAE2-ABBE-4A46-9306-9B3319C4517EQ29248715-E61A57AC-5450-49A1-BCE4-A27F109E7686Q30235360-97CCD94D-2570-4BB6-86DE-A9B70103F8B1Q30275266-8C0FAC72-63FB-4168-A750-CD73BEBD4919Q31145059-AFD88C85-8333-4219-A78D-F23AECCF1B04Q33571115-76DDF397-8A13-48D4-A4A7-62F48AC1414FQ33618747-9D733CBB-E650-4FA0-80E7-DF61150626AAQ33645595-611214CD-B352-43C8-A32F-F28FFE12112AQ33704088-36BA741E-7615-4ABF-B7C0-4449710E7A2DQ33738756-7C76FD27-20D2-4A3D-A568-C3E5B815F6F4Q33793552-A156BBC4-3FA2-4074-8BB7-F49A80381485Q33813057-16BE4F84-52F8-4FF6-849B-11FEB3B90F04Q33813378-BE198ACC-B732-41CF-9740-2D20ECD04E7FQ33832752-13BADA8C-0A40-4BE0-A0D1-1FDA61572DF8Q34538075-8BD52959-CF80-4E24-B5E2-D49BDCF53A84Q36024656-E8D8AEC1-BE6A-4257-BC72-6A2CD8C56E10Q36142491-F6DFF0FE-AA77-4C6C-B7CF-4EF5F5CD7FEFQ36222304-A799A780-1EAA-44E7-AC28-3A91CE440933Q36295004-780C0B4A-4C87-4CCF-B870-C0AA0732CC40Q36380295-32645FD7-BB3D-4918-A99A-AAE1E4DC280DQ36400381-4BE1492C-F88F-468D-AA2F-ECEB5BD15D92Q37306007-B03E9E7C-A1E6-4E58-896B-C251689DE4A7Q37309882-4D1837FE-FC1D-4334-A454-774C79904386Q37552085-FF3EDB3F-9776-4EA3-BF11-63CD3AFBBD0DQ37584395-60DAF1B0-20EB-4023-9F0D-BEBE72171EA2Q37628005-5D3E95BD-F7BB-4B48-A1DE-E2C4C56B8558Q37629874-C894192A-BF31-4427-A591-40C851875470Q37637905-1DD31331-D95B-45D7-9B67-BF02AC4FDF45Q37660698-840101B9-D2DB-498E-A6D9-00A3FAF1CEE0Q37664203-E1F9B4BE-C55F-4ACA-9E9A-64ED388CCE8D
P2860
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@ast
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@en
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@nl
type
label
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@ast
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@en
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@nl
prefLabel
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@ast
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@en
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@nl
P2093
P921
P3181
P1433
P1476
Atezolizumab versus docetaxel ...... 2 randomised controlled trial.
@en
P2093
Achim Rittmeyer
Alan Sandler
Alexander Spira
Angel Artal-Cortes
Conrad Lewanski
Daniel S Chen
Daniel Waterkamp
David Smith
Fadi Braiteh
P304
P3181
P356
10.1016/S0140-6736(16)00587-0
P407
P577
2016-04-30T00:00:00Z